KLRS Stock Price, Chart, Stats & News

Kalaris Therapeutics Inc
Save
Kalaris Therapeutics Inc (KLRS) does not currently pay a dividend.
75.56M
Market cap
–
Current P/E
–
Forward P/E
KLRS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -35.68% |
ROE | -73.11% |
D/E | 0.02x |
Interest coverage ratio | -31.98x |
KLRS valuation
P/E | – |
P/S | – |
P/B | 1.57x |
P/CF | -2.87x |
P/FCF | -2.33x |
P/OCF | -2.87x |
PEG | -0.07x |
EV multiple | -4.61x |
About
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases.
Similar securities
Based on sector and market capitalization
Report issue











